, our findings indicate that APCDD1 may regulate a diversity of biological processes controlled by Wnt signalling.
Hair follicle miniaturization is a degenerative process that proportionally reduces the dimensions of the epithelial and mesenchymal compartments of the hair follicle, and leads to the conversion of thick, terminal hair to fine, vellus hair 4 . It is most commonly observed in androgenetic alopecia, but is also characteristic of a rare, autosomal dominant form of hair loss, known as hereditary hypotrichosis simplex 1 (HHS; OMIM accession 146520) (Supplementary Note). To gain insight into the molecular underpinnings of hair follicle miniaturization and identify a gene underlying HHS, we performed a linkage study in two Pakistani families (HHS1 and HHS2) (Fig. 1a-d and Supplementary Fig. 1a-l) . After excluding the CDSN locus on chromosome 6 (ref. 5) , we used Affymetrix 10K single nucleotide polymorphism (SNP) arrays for genotyping. Linkage analysis using a dominant model yielded a maximum log odds ratio (lod) score of Z 5 4.6 on chromosome 18p11.22 ( Supplementary Fig. 1m ). We narrowed the candidate interval to a 1.8-megabase (Mb) region (Fig. 1e ) containing eight genes, four pseudogenes and three predicted transcripts ( Supplementary Fig. 1n ). Direct sequencing identified a heterozygous mutation 26T.G (Leu9Arg) in the signal peptide of the APCDD1 gene ( Supplementary Fig. 1o ) 6 . The Leu9Arg mutation cosegregated with the disease phenotype in both families, and was absent in 200 unrelated, unaffected controls and in the SNP databases (Supplementary Fig. 1p ; data not shown). Unexpectedly, we identified the identical APCDD1 mutation in an Italian family with autosomal dominant HHS, which had previously been mapped to the same region of chromosome 18p11.22 (Supplementary Fig. 2 ) 7 , providing independent genetic evidence in support of this finding.
APCDD1 was abundantly expressed in both the epidermal and dermal compartments of the human hair follicle, consistent with a role in hair follicle miniaturization. APCDD1 messenger RNA and protein were present in human scalp skin by reverse transcription PCR (RT-PCR) ( Supplementary Fig. 3a) , and a western blot using an APCDD1 antibody (Fig. 1l) . APCDD1 mRNA and protein were highly expressed in the hair follicle dermal papilla, the matrix, and the hair shaft ( Fig. 1f-j) . Apcdd1 orthologues are conserved throughout vertebrate evolution ( Supplementary Fig. 4a, b) , suggesting that a role in mouse (also called Drapc1) 3 and human hair follicle growth emerged recently in mammalian species.
Several lines of evidence led us to postulate that APCDD1 may function as a negative regulator of Wnt signalling, including the observation that it is a direct target gene of Wnt/b-catenin 6 ; its similarity in expression pattern with another Wnt inhibitor, Wise 8 ; the abundance of Wnt inhibitors in the hair follicle 9 ; and the conservation of 12 cysteine residues ( Supplementary Fig. 4a ), a structural motif important for interaction between Wnt ligands and their receptors 10, 11 . To test whether APCDD1 is an inhibitor of Wnt signalling, we first determined whether APCDD1 interacts with ligands and receptors of the canonical Wnt pathway. No interaction was found with FZD2, FZD8 and DKK4 (data not shown). In contrast, the extracellular domain of APCDD1 (APCDD1DTM) co-precipitated with recombinant tagged forms of WNT3A and LRP5, two proteins important for hair follicle induction 12 ( Fig. 2a and Supplementary Figs 3b and 5 ), suggesting that APCDD1 can modulate the Wnt pathway by potential interactions with WNT3A and LRP5 at the cell surface. To determine the effect of APCDD1 on Wnt signalling, we performed TOP/FOPflash (T-cell factor (TCF)-responsive and negative control luciferase reporter) Wnt reporter assays in HEK293T cells. Reporter activity induced by WNT3A alone, or in combination with LRP5 and FZD2, was downregulated ,2-fold by APCDD1 in a dose-dependent manner (Fig. 2b) , indicating that APCDD1 inhibits the Wnt/bcatenin pathway.
To determine whether APCDD1 can function as a Wnt inhibitor in vivo, we selected two systems in which the role of the Wnt/b-catenin pathway has been well-defined: neuronal specification in the developing spinal cord [13] [14] [15] and axis determination in the frog 16, 17 . In the chick spinal cord, a Wnt/b-catenin gradient promotes proliferation of neural progenitors and generation of some neuronal classes [13] [14] [15] . Transfection of the Wnt reporter TOP::eGFP (T cell factor responsive enhanced green fluorescent protein reporter) in the chick neural tube showed strong activation of the pathway in the dorsal and intermediate progenitors, as previously shown 15 . However, overexpression of APCDD1 strongly reduced eGFP expression levels ( Supplementary Fig. 6a-d) , decreased the number of SOX3 1 neural progenitors by ,20-30%, and also decreased various neuronal subtypes of dorsal and ventral origin (Fig. 3a-e and Supplementary Fig. 7a-d ). This effect was stronger with mouse Apcdd1 (mApcdd1), a closer orthologue of the chick protein (Supplementary Figs 8a-i and 9a-e). These findings are consistent with the hypothesis that APCDD1 functions as a Wnt inhibitor.
The maternal Wnt pathway is required for the formation of dorsal and anterior structures in early Xenopus embryos 18, 19 . Overexpression of APCDD1 in dorsal blastomeres (n 5 35) reduced the anterior structures, such as the eyes and cement gland, at the tadpole stage (Fig. 4a,  b) , consistent with maternal Wnt inhibition. APCDD1 also inhibited transcription of the siamois (sia) reporter gene (Fig. 2c) , activated by the maternal Wnt pathway 20 . A zygotic Wnt pathway is subsequently activated on the ventral side of the embryo 21 , and its inhibition produces secondary axes with incomplete heads 16, 17 . Ventral overexpression of APCDD1 induced secondary axes (n 5 43, 28% duplicated axes; Fig. 4c, d ), consistent with an inhibitory effect on zygotic Wnt signalling. The inhibition of Wnt activity by APCDD1 was also seen in transcription assays with wnt8 RNA, but not b-catenin (Fig. 2c) , indicating that it acts upstream of b-catenin.
We next investigated which domain of APCDD1 mediates its activity and in which cell APCDD1 exerts its function. First, western blot of APCDD1 expressed in HEK293T cells showed that the protein is glycosylated and forms a dimer ( Supplementary Fig. 10a-c) . Second, misexpression of mApcdd1DTM (lacking the transmembrane domain) in the chick neural tube mimicked the effects observed with wild-type mApcdd1 (Supplementary Figs 8j-r and 9f-j), suggesting that the Wnt inhibitory activity resides in the extracellular domain. Third, APCDD1 could affect either the signalling cell, by regulating Wnt secretion 22 , or the receiving cell. In Xenopus transcription assays, wnt8 RNA injected in one cell activated the sia reporter in an adjacent cell. Human APCDD1 RNA inhibited transcription when co-injected with the sia reporter, but not with wnt8 (Fig. 4h) , suggesting that APCDD1 inhibits Wnt signalling cell-autonomously in the receiving cell. Last, because wild-type APCDD1 contains a transmembrane domain (Fig. 1k) , and was localized to the plasma membrane ( Fig. 2h and Supplementary Fig. 11a, c, f , i), we tested whether APCDD1 undergoes cleavage to generate a diffusible inhibitor (APCDD1DTM); however, it was undetectable in the medium of transfected cells (Supplementary Fig. 10d) . Collectively, these data show that APCDD1 is probably a membrane-tethered Wnt inhibitor that acts as a dimer at the surface of the Wnt-receiving cell.
The Leu9Arg mutation disrupts the hydrophobic core of the signal peptide critical for co-translational processing (Supplementary . We analysed protein stability and localization by western blotting and immunofluorescence in two cell lines (HEK293T or Bend3.0) transfected with either wild-type APCDD1 or two different mutant forms (pathogenic mutation, Leu9Arg, and conservative substitution, Leu9Val). Two fragments (68 kilodalton (kDa) and 130 kDa) were detected in lysates of the wild-type and APCDD1(L9V)-transfected cells, whereas only a faint 68 kDa fragment was detected in the Leu9Arg mutant (Fig. 2f ). In addition, wild-type or APCDD1(L9V) protein was localized to the cell membrane, whereas APCDD1(L9R) was retained within the endoplasmic reticulum (ER) (Fig. 2h, i and Supplementary Fig. 11a-j) . Furthermore, unlike the wild-type isoform, amino-terminally GFP-tagged APCDD1(L9R) could not be cleaved to localize at the membrane (Supplementary Fig. 11l-n) . Finally, when the wild-type and APCDD1(L9R) were either co-transfected in cells or injected into Xenopus embryos, some wildtype protein was degraded (Fig. 2e, g ), and the rest was sequestered in the ER along with the Leu9Arg isoform (Fig. 2j, k and Supplementary  Fig. 11k , o-r). Therefore, the Leu9Arg mutation probably functions in a dominant-negative manner, to destabilize the wild-type protein and prevent it from reaching the plasma membrane.
We next tested whether the Leu9Arg mutation affects APCDD1 protein function in vivo. In the chick neural tube, expression of APCDD1(L9R) only weakly inhibited eGFP transcription from the Wnt reporter ( Supplementary Fig. 6e , f), and had no effect on SOX3 neural progenitors and neuronal subtypes ( The same results were observed in Xenopus, where the inhibitory effect of wild-type APCDD1 on wnt8-induced transcription was blocked by co-expression of the Leu9Arg mutant (Fig. 2d) .
We then determined the consequences of Xenopus apcdd1 (Xapcdd1) protein depletion on axis formation in Xenopus embryos. Xapcdd1 mRNA is expressed maternally throughout development, with the highest levels in animal (future ectoderm) and marginal (future mesoderm) cells of stage ten embryos ( Supplementary Fig. 12 ). Depletion of Xapcdd1 protein with a specific translation-blocking morpholino oligonucleotide (MO) ( Supplementary Fig. 13 ) resulted in loss of anterior and dorsal structures ( Fig. 4e and Supplementary Table 1) . This phenotype was rescued by injection of either MO-resistant 59 mutant Xapcdd1 RNA, or of dominant-negative wnt8 RNA (Fig. 4f, Therefore, the loss-of-function phenotype is consistent with ectopic activation on the dorsal side of zygotic Wnt activity, and supports the notion that endogenous APCDD1 is a Wnt inhibitor.
In conclusion, we suggest that APCDD1 may prevent formation of the Wnt receptor complex (Fig. 4i) as it interacts in vitro with LRP5 and WNT3A. The Leu9Arg mutant is unable to repress Wnt-responsive genes, by trapping the wild-type protein in the ER where it may undergo degradation (Fig. 4i) .
Our findings underscore the requirement for controlled regulation of the Wnt signalling pathway in hair follicle morphogenesis and cycling 25 . It is known that perturbation of Wnt signaling in mouse models leads to increased hair follicle density when Wnt signaling is constitutively activated in the epidermis 26 , and a loss of hair when Lef1 is deleted 27 . We postulate that in HHS, Wnt signalling is indirectly increased through the loss of the inhibitory function of APCDD1 in both the epidermal and dermal compartments of the hair follicle, although the lack of HHS scalp samples precluded us from verifying this assumption. This notion is supported by mice with targeted ablation of another Wnt inhibitor, klotho (Kl), which show a reduction in hair follicle density due to indirect upregulation of Wnt signalling and a depletion of hair follicle bulge stem cells 28 . As APCDD1 is expressed in both epidermal hair follicle cells and the dermal papilla, we postulate that the simultaneous deregulation of Wnt signalling in both compartments may lead to a proportional reduction in organ size of the hair follicle, resulting in miniaturization.
Our study provides the first genetic evidence, to our knowledge, that mutations in a Wnt inhibitor result in hair loss in humans. APCDD1 may be implicated in polygenic hair follicle disorders as well, because it resides within linkage intervals on chromosome 18 in families with androgenetic alopecia 29 as well as alopecia areata 30 . Furthermore, because APCDD1 is expressed in a broad range of cell types 3 , our findings raise the possibility that APCDD1 is involved in other Wnt-regulated processes, such as morphogenesis, stem-cell renewal, neural development and cancer.
METHODS SUMMARY
Linkage analysis. Genome-wide SNP-based genotyping was performed using the Affymetrix Human Mapping 10K 2.0 Array. Quality control and data analysis was performed with Genespring GT (Agilent software). SNPs that violated a Mendelian inheritance pattern were removed from the data set before analysis. Haplotypes were inferred from raw genotype data. By analysing haplotypes rather than individual SNPs, type I error introduced by linkage disequilibrium between markers is mitigated. Finally, haplotypes were analysed for linkage under the assumption of a fully penetrant disease gene with a frequency of 0.001 transmitted by a dominant mode of inheritance. Mutation analysis. Using the genomic DNA of the family members, all exons and exon--intron boundaries of the human APCDD1 gene were amplified by PCR with the gene-specific primers (Supplementary Table 2 ). The PCR products were directly sequenced in an ABI Prism 310 Automated Sequencer, using the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems). The mutation 26T.G disrupts a DdeI restriction enzyme site, which was used to screen the family members and control individuals.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Clinical details and DNA extraction. Informed consent was obtained from all subjects and approval for this study was provided by the Institutional Review Board of Columbia University. The study was conducted in adherence to the Declaration of Helsinki Principles. Peripheral blood samples were collected from the family members as well as unrelated healthy control individuals of Pakistani and European origin (200 individuals each). Genomic DNA was isolated from these samples using the PUREGENE DNA isolation kit (Gentra System). Genotyping. Genomic DNA from members of two Pakistani families was amplified by PCR using Platinum PCR SuperMix (Invitrogen) and primers for microsatellite markers on chromosome 18p11. The amplified products were analysed on 8% polyacrylamide gels. Mutation analysis of the APCDD1 gene. Exon 1 and the adjacent boundary sequences of the APCDD1 gene were amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen). Owing to the high G/C content, dimethylsuphoxide (DMSO) (final 5%) and MgSO 4 (final 1.6 mM) were added to the PCR reaction. Other exons, as well as the exon-intron boundaries of the APCDD1 gene, were amplified using Platinum PCR SuperMix (Invitrogen). Primer sequences are shown in Supplementary Table 2 .
To screen for the mutation 26T.G (Leu9Arg), a part of exon 1 and intron 1 of the APCDD1 gene was amplified by PCR using Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and the following primers: forward (59-CCAGAGC AGGACTGGAAATG-39) and reverse (59-CGCCAAGGGGACAGTGTAG-39). The amplified PCR products, 191 base pairs in size, were digested with DdeI at 37 uC overnight, and run on 2.0% agarose gels. Cell culture. HEK293T (human embryonic kidney) and Bend3.0 cells were cultured in DMEM; GIBCO) supplemented with 10% FBS (GIBCO), 100 international units (IU) ml 21 penicillin and 100 mg ml 21 streptomycin. For transfection experiments in HEK293T cells, dishes were coated with a coating medium containing 0.01 mg ml 21 of fibronectin (Sigma) and 0.03 mg ml 21 of type I collagen (Sigma) before seeding the cells in to prevent detachment of the cells. Anti-APCDD1 antibodies. A mouse polyclonal anti-human APCDD1 antibody was purchased from Abnova. This antibody was raised against the full-length hAPCDD1 protein. We performed epitope-mapping using three truncated glutathione S-transferase (GST)-APCDD1 proteins (amino acid residues 1-171, 166-336 and 331-514), and confirmed that the epitope of the antibody exists between residues 166 and 336 of the hAPCDD1, which corresponds to the middle portion of the extracellular domain (data not shown). This antibody recognized hair shaft and dermal papilla in human hair follicles (Fig. 1g-j) , which finely overlapped with the signals detected by in situ hybridization (Fig. 1f ). An affinity-purified rabbit polyclonal anti-mApcdd1 antibody was produced by immunizing rabbits with the synthetic peptide, CQRPSDGSSPDRPEKRATSY (corresponding to the carboxy terminus of the extracellular domain of the mApcdd1 protein, residues 441-459) conjugated to keyhole limpet haemocyanin (KLH; Pierce). This region is completely conserved among mouse and human APCDD1 proteins. The antibody was affinity-purified from the serum using the Sulfolink immobilization column (Pierce). This antibody strongly recognized hAPCDD1 protein in western blots and immunofluorescence. RT-PCR in human scalp skin and plucked hairs. Total RNA was isolated from scalp skin and plucked scalp hairs of healthy control individuals using the RNeasy Minikit (Qiagen). Two micrograms of total RNA was reversetranscribed with oligo-dT primers and SuperScript III (Invitrogen). The complementary DNAs were amplified by PCR using Platinum PCR SuperMix and primer pairs for APCDD1, APCDD1L, keratin 15 (KRT15), LRP5, WNT3A, and b-2 microglobulin (B2M) genes (Supplementary Table 2 ). Primers for the KRT15, LRP5 and WNT3A genes were designed as described previously 31, 32 . PCR products were run on 1.5% agarose gels. Expression vectors. cDNA sequences for human APCDD1, WNT3A, CD40 and LRP5 were amplified by PCR using primers and templates shown in Supplementary Table 2 . The amplified products were subcloned into the mammalian expression vector pCXN2.1 (ref. 33 ), a slightly modified version of pCXN2 (ref. 34 ) with several cloning sites. The expression construct for the full-length human LRP5 was provided by P. Ducy. To generate the expression construct for mouse Fzd2, the full-length open reading frame of Fzd2 was purchased from Invitrogen (clone ID 6411627), which was subcloned into the NotI sites of the pCXN2.1 vector. To introduce a Flag-tag between amino acids 35 and 36 of the APCDD1 protein, the N-terminal region of the APCDD1 was PCRamplified using a forward primer (APCDD1-F-XhoI in Supplementary Table 2) and a reverse primer (APCDD1-R-Flag-AvrII: 59-AAAACCTAGGCTTATCGTC GTCATCCTTGTAATCATGAGACCTGCTGTCTGGAT-39), which was followed by digestion with restriction enzymes XhoI and AvrII. The C-terminal region of the APCDD1 and the truncated APCDD1 proteins with the C-terminal HA-tag were obtained through digestion of the pCXN2.1-Wt-APCDD1-HA and pCXN2.1-APCDD1-DTM-HA constructs with restriction enzymes AvrII and NheI. These two fragments were ligated with the AvrII site, and subsequently subcloned into the XhoI and NheI sites of the pCXN2.1 vector. To generate expression constructs for N-terminal GFP-tagged APCDD1 protein, the coding region of the APCDD1 and the rabbit b-globin 39-flanking sequences were cut out from the pCXN2.1-APCDD1 constructs with restriction enzymes XhoI and BamHI, and subcloned in frame into the pEGFP-C1 vector (Clontech). The templates were also subcloned into the XhoI and BamHI sites of pBluescript-SK (2) vector (Stratagene). pGEM wnt8 (from R. Harland), the sia luciferase reporter gene (from D. Kimmelman), and pSP36 b-catenin (from B. M. Gumbiner) have been previously described.
To generate a Xenopus expression vector for Xenopus apcdd1, we used a fulllength cDNA clone (BC080377, from Open Biosystems) as a template and amplified the open reading frame with the primers shown in Supplementary Table 2 . The PCR product was inserted as a ClaI/SalI fragment in CS212XHA (A. Vonica), resulting in CS21Xapcdd1-HA.
The full-length mouse Apcdd1 cDNA was amplified by RT-PCR from brain endothelial cells using the First Strand Synthesis Kit and High Fidelity Amplification Kit (Roche Applied Science) with primers shown in Supplementary Table 2 , and then subcloned into pCRII-TOPO (Invitrogen) and pCAGGS 34 vectors for in vitro transcription and chick neural tube electroporations, respectively. The Apcdd1DTM isoform containing the extracellular domain of mApcdd1 (residues 1-486) was amplified by PCR from the full-length cDNA using primers shown in Supplementary Table 2 and subcloned into pCAGGS vector for chick electroporation. Chick neural tube electroporations. The full-length wild-type, APCDD1(L9R), APCDD1(L9V), mApcdd1 or mApcdd1DTM isoforms were subcloned into the pCAGGS vector and transfected into the chick neural tube (stage 12-13) together with nuclear GFP vector (pCIG) using in ovo electroporation as described 35 . The chick embryos were grown for 3-4 more days in the 39 uC incubator, fixed with 4% paraformaldehyde (PFA), 0.1 M phosphate buffer, washed and cryoprotected as described 35 before being processed for in situ hybridization or immunofluorescence. For the Wnt reporter assays, the TOP::eGFP reporter (M38 TOP::eGFP from Addgene) was transfected alone or in combination with wild-type APCDD1 or APCDD1(L9R). The chick embryos were grown for 12 h in the 39 uC incubator, fixed with 4% PFA, 0.1M phosphate buffer for 30 min, washed and cryoprotected as described 35 , before being processed for immunofluorescence. Cell counts and statistical analysis. Spinal cord SOX3 1 progenitors, ISL1/2 1 ventral motor neurons, ISL1/2 1 dorsal interneurons and CHX10 1 V2a interneurons were counted from eight independent 12-mm thick sections of chick spinal cord from each transfected embryo. The nucleus stained with the transcription factor was considered one cell for this purpose. The cells were counted from both the electroporated side and the opposite control side. The plots were created using Sigma plot with values representing the mean for each embryo. Statistical significance was determined using the Student's t-test. Transient transfections and western blots in cultured cells and human scalp skin. HEK293T or Bend3.0 cells were plated in 60-mm dishes the day before transfection. Expression plasmids of APCDD1 were transfected with FuGENE 6 (Roche Applied Science) at 60% confluency for HEK293 cells, or with Targefect_HUVEC for Bend3.0 cells. The total amount of transfected plasmids was adjusted with the empty pCXN2.1 vector. The cells were cultured 48 h after transfection in Opti-MEM (GIBCO). The cells were collected and homogenized by sonication in homogenization buffer (25 mM HEPES-NaOH, pH 7.4, 10 mM MgCl 2 , 250 mM sucrose and Complete Mini Protease Inhibitor Cocktail (Roche Applied Science)). The cell debris was removed by centrifugation at 800g for 10 min at 4 uC, and the supernatant was collected as cell lysates. N-glycosidase (PNGase F) treatment and extraction of membrane fraction were performed as described previously 33 . The cultured medium with Complete Mini Protease Inhibitor Cocktail was centrifuged at 300g for 5 min at 4 uC. The supernatant was purified with 0.45 mm syringe filters (Thermo Fisher Science), and concentrated using Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10 Membrane (Millipore) according to the manufacturer's recommendations. Total cell lysates from human scalp skin were extracted by homogenization in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% NP40, 0.5% sodium deoxycholate, 0.1% SDS and Complete Mini Protease Inhibitor Cocktail. All samples were mixed with an equal amount of Laemmli Sample Buffer (Bio-Rad Laboratories) containing 5% b-mercaptoethanol, boiled at 95 uC for 5 min, and analysed by 10% SDS-PAGE. Western blots were performed as described previously 36 . The primary antibodies used were rabbit polyclonal anti-HA (diluted 1:4,000; Abcam), rabbit polyclonal anti-APCDD1 (1:20,000), mouse polyclonal anti-APCDD1 (1:1,000; Abnova), mouse monoclonal anti-Flag M2 (1:1,000; Sigma), and rabbit polyclonal anti-b-actin (1:10,000; Sigma).
Wnt reporter assays in HEK293T cells. HEK293T cells were seeded in 12-well dishes the day before transfection. One-hundred nanograms of either TOP-flash (active) or FOP-flash (inactive) Wnt reporter vector (gifts from P. Ducy) was transfected into each well along with constructs for WNT3A (200 ng), FZD2 (100 ng), LRP5 (100 ng), and/or wild-type APCDD1-HA (300 ng or 800 ng) using Lipofectamine 2000 (Invitrogen). A construct for the b-galactosidase reporter (100 ng) was also transfected for normalization of transfection efficiency. The cells were lysed 36 h after transfection and the signals were assayed as described previously 9 . The Wnt activity was measured based on the ratio of TOP/FOP luciferase activity. The results represent triplicate determination of a single experiment that is representative of a total of five similar experiments. Co-immunoprecipitation assays. Expression plasmids (total 4 mg) were transfected into HEK293T cells seeded on 60-mm dishes with FuGENE 6 (Roche Applied Science) at 60% confluency. Twenty-four hours after the transfection, the cells were collected and homogenized in lysis buffer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 10% Glycerol, 2 mM EDTA, 0.5% Triton X-100, and Complete Mini Protease Inhibitor Cocktail). Total cell lysates were collected by centrifugation at 16,000 g for 15 min at 4 uC. The samples were incubated with either mouse monoclonal anti-Flag M2 agarose gel (Sigma) or mouse monoclonal anti-HA agarose gel (Sigma) for 3 h at 4 uC. The agarose beads were washed with lysis buffer five times. The precipitated proteins were eluted with NuPAGE lithium dodecyl sulphate (LDS) sample buffer containing Sample Reducing Agent (Invitrogen), incubated at 75 uC for 10 min, and separated on 10% NuPAGE gels (Invitrogen). Western blots were performed using anti-HA (Abcam) and anti-Flag M2 antibodies (Sigma). GST pulldown assays. To express the GST-fusion APCDD1 protein in bacteria, the extracellular domain of hAPCDD1 (residues 28-486) was PCR-amplified (Supplementary Table 2 ), and subcloned in-frame into the EcoRI and XhoI sites of pGEX-4T-3 vector (GE Healthcare Life Sciences). Expression of GST-fusion proteins was induced in DH5a (Invitrogen) by the addition of 0.1 mM isopropylb-D-thiogalactopyranoside at 37 uC for 3 h, and the fusion proteins were isolated from bacterial lysates by affinity chromatography with Glutathione Sepharose beads (GE Healthcare Life Sciences). LRP5-EC-Flag, WNT3A-HA or CD40-EC-HA were overexpressed in HEK293T cells. GST pulldown assays were performed as described previously 37 . The antibodies used were rabbit polyclonal anti-GST (1:3,000; Santa Cruz Biotechnology), anti-HA (Abcam) and anti-Flag M2 (Sigma). In situ hybridization. A part of the human APCDD1 cDNA (GenBank Accession number, NM_153000: nucleotides 338-1899) was cloned into pCRII-TOPO vector (Invitrogen). The antisense and sense digoxigenin (DIG)-labelled complementary RNA probes were synthesized from the linearized vectors with T7 and SP6 RNA polymerases (Roche Applied Science), respectively. In situ hybridization on dissected human hair follicles was performed following the methods described previously with minor modifications 38 . In situ hybridizations on chick spinal cord sections were performed as described 39 . The antisense mouse Apcdd1 mRNA was generated using the in vitro transcription kit (Roche) with T7 RNA polymerase. The antisense chick SIM1 mRNA was generated using the T3 RNA polymerase. Indirect immunofluorescence. Indirect immunofluorescence on cultured cells and fresh frozen sections of individually dissected hair follicles was performed as described previously 36 . Indirect immunofluorescence on HEK293T and Bend3.0 cells was performed 48 h after the APCDD1 expression constructs were transfected. For some stainings, the cell membrane was labelled with rhodaminephalloidin (Invitrogen). The primary antibodies used were mouse polyclonal anti-APCDD1 (diluted 1:1,000; Abnova), rabbit polyclonal anti-APCDD1 (1:4,000), rabbit polyclonal anti-pan-cadherin (1:200; Invitrogen), and goat polyclonal anti-calnexin (1:200; Santa Cruz Biotechnology). Immunofluorescence on chick spinal cord sections was performed as described 40 . The monoclonal antibodies against NKX2.2, PAX6, PAX7, EN1 and EVX1 were purchased from DSHB; rabbit anti-OLIG2 (Chemicon), rabbit anti-SOX3 (provided by S. Wilson), rabbit anti-CHX10, guinea pig anti-ISL1/2, sheep anti-GFP (Biogenesis) and mouse anti-b3-tubulin (TUJ1; Covance) were used as described 40 .
Quantification of subcellular localization of APCDD1 protein. On the basis of the results of immunofluorescence with a rabbit polyclonal anti-APCDD1 antibody in HEK293T cells transfected with APCDD1-expression constructs, we measured the subcellular localization of APCDD1 proteins. The cell outline was visualized using rhodamine-phalloidin (Invitrogen). Images were processed in Image J (http:// rsbweb.nih.gov/ij/), splitting the channels. First, the outline of the cell was used to measure the signal within the whole cell. Second, scaling the cell frame down, the signal inside the cell was measured. For each cell, the following values were recorded: (1) the adjusted total signal in the cell (the level of fluorescence, relative to the background); (2) the adjusted signal inside the cell; (3) the adjusted signal in the membrane; and (4) the ratio between adjusted signal in the membrane and inside the cell. The adjusted signal (S adj ) was calculated by subtracting the background signal and then normalizing to the background (B) signal levels in an empty area of equal size within the same image. S adj 5 (S 2 B)/B. For example, a reported signal S adj 5 5 indicates five times stronger than the background
